Cargando…

A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine

Ubrogepant is an innovative medication designed for the acute treatment of migraine, a debilitating neurological condition that profoundly impairs quality of life, productivity, and social interactions. This comprehensive review assesses the efficacy, safety, tolerability, and mechanism of action of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dighriri, Ibrahim M, Nazel, Shahad, Alharthi, Aeshah M, Altowairqi, Nasreen A, Albariqi, Aqeel M, Tohari, Mona A, Alameer, Atheer A, Alsaran, Amjad K, ALshammari, Fares R, AlMutairi, Naif F, Alsubaie, Fahad M, Alharbi, Turki A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693258/ https://www.ncbi.nlm.nih.gov/pubmed/38046695 http://dx.doi.org/10.7759/cureus.48160

Ejemplares similares

Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
por: Jakate, Abhijeet, et al.
Publicado: (2020)

Ubrogepant: First Approval
por: Scott, Lesley J.
Publicado: (2020)

Ubrogepant to Treat Acute Migraine in Adults
por: Edinoff, Amber N., et al.
Publicado: (2021)

Correction to: Ubrogepant: First Approval
por: Scott, Lesley J.
Publicado: (2020)

An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment
por: Arishi, Naif A, et al.
Publicado: (2023)

Mechanistic Investigations Support Liver Safety of Ubrogepant
por: Smith, Brenda, et al.
Publicado: (2020)

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
por: Goadsby, Peter J, et al.
Publicado: (2020)

Ubrogepant in the Acute Management of Migraine: A Narrative Review
por: Chiang, Chia-Chun, et al.
Publicado: (2021)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males
por: Ankrom, Wendy, et al.
Publicado: (2020)

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
por: Lipton, Richard B., et al.
Publicado: (2022)

The Effect of Coronal Pre-flaring and Type of Root Canal Irrigation on Working Length Accuracy Using Electronic Apex Locators
por: Rifaat, Shimaa, et al.
Publicado: (2023)

Influences of Different CAD/CAM Ceramic Compositions and Thicknesses on the Mechanical Properties of Ceramic Restorations: An In Vitro Study
por: Ellakany, Passent, et al.
Publicado: (2023)

Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache
por: Navratilova, Edita, et al.
Publicado: (2020)

Parent Awareness and Perceived Barriers Regarding Hearing Impairment among School Age Children in Taif Region of Saudi Arabia
por: Fageeh, Yahya A., et al.
Publicado: (2023)

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults
por: Goadsby, Peter J, et al.
Publicado: (2019)

Effect of Different Scaling Methods on the Surface Topography of Different CAD/CAM Ceramic Compositions
por: Ellakany, Passent, et al.
Publicado: (2023)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis
por: Zhang, Zizhen, et al.
Publicado: (2021)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
por: Ailani, Jessica, et al.
Publicado: (2020)

Prevalence and public knowledge regarding tooth bleaching in Saudi Arabia
por: AlOtaibi, Ghada, et al.
Publicado: (2020)

Short- and Long-Term Effects of Vitamin D Treatment on Bacillus Calmette-Guerin-Induced Depressive-Like Behavior in Mice
por: Saleh, Lobna A, et al.
Publicado: (2021)

Adverse Events of COVID-19 Vaccination among the Saudi Population: A Systematic Review and Meta-Analysis
por: Alhossan, Abdulaziz, et al.
Publicado: (2022)

Hydatid Cyst of the Thigh: A Report of a Rare Case With Literature Review
por: Khan, Arshadullah, et al.
Publicado: (2023)

Correlation between Subclinical Hypothyroidism and Metabolic Syndrome: A Retrospective Study
por: Alsulami, Salhah Saleh, et al.
Publicado: (2023)

Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
por: Hutchinson, Susan, et al.
Publicado: (2021)

Awareness and Knowledge of Amblyopia: A Cross-Sectional Study Among the Population of Hail City, Saudi Arabia
por: Almutairi, Manahel S, et al.
Publicado: (2022)

Single‐Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Nd:YAG laser therapy for non-resolving premacular subhyaloid hemorrhage in Saudi patients
por: Allam, Khalid, et al.
Publicado: (2019)

Prevalence of energy drink consumption and association with dietary habits among governmental university students in Riyadh
por: Alafif, Nora, et al.
Publicado: (2021)

Assessment of the Prevalence of the Use of Nasal Decongestants Among the General Population in Saudi Arabia
por: Alharthi, Ahmad S, et al.
Publicado: (2022)

Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial
por: Jakate, Abhijeet, et al.
Publicado: (2019)

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
por: Manack Adams, Aubrey, et al.
Publicado: (2023)

Unusual bilateral panuveitis uveitis with brucellosis
por: AlMutairi, Naif, et al.
Publicado: (2022)

Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment
por: Li, Chi‐Chung, et al.
Publicado: (2020)

Risk factors of SARS-CoV-2 infection in cancer patients pre- and post-vaccination
por: Alsagaby, Suliman A., et al.
Publicado: (2022)

KRAS G12C-Mutant Non-Small-Cell Lung Adenocarcinoma: First Documented Report in the Arabian Gulf
por: Alsulaiman, Abdullah S, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_flk4amuc8i4vo14lua8oanpqtr